Vaptans: A potential new approach for treating chronic hyponatremia in psychotic patients

Clinical Schizophrenia and Related Psychoses

Volumn 6, Issue 1, 2012, Pages 21-26

  Josiassen, Richard C ^a,b   Curtis, Jessica L ^a   Shaughnessy, Rita A ^a,b   Filmyer, Dawn M ^a   Geboy, Alexander G ^a   Skuban, Nina ^c   Ouyang, John ^d   Czerwiec, Frank ^d  

^a Translational Neuroscience LLC   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Worldwide Clinical Trials   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Hyponatremia; Schizophrenia; Tolvaptan; Vaptans; Vasopressin antagonists

Indexed keywords

SODIUM; TOLVAPTAN;

ADULT; ARTICLE; CHRONIC IDIOPATHIC HYPONATREMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; HAND FRACTURE; HUMAN; HYPONATREMIA; LACERATION; MALE; OPEN STUDY; PSYCHOSIS; SODIUM BLOOD LEVEL; THORAX PAIN; TOOTH PAIN;

ADMINISTRATION, ORAL; ADULT; BENZAZEPINES; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; HUMANS; HYPONATREMIA; LONG-TERM CARE; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RECEPTORS, VASOPRESSIN; SODIUM; TREATMENT OUTCOME;

EID: 84859719561     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.6.1.3     Document Type: Article

References (21)

1. Verghese C, de Leon J, Josiassen RC. Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia. Schizophr Bull 1996;22(3):455-464. (Pubitemid 26295348)
2. Siegel AJ. Hyponatremia in psychiatric patients: update on evaluation and management. Harv Rev Psychiatry 2008;16(1):13-24. (Pubitemid 351317185)
3. Josiassen RC, Curtis J, Filmyer DM, Audino B, Skuban N, Shaughnessy RA. Tolvaptan: a new tool for the effective treatment of hyponatremia in schizophrenia. Expert Opin Pharmacother 2010;11(4):637-648.
4. Adrogue HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol 2005;25(3):240-249. (Pubitemid 41202746)
5. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11 Suppl 1):S1-21.
6. Vieweg WV, Rowe WT, David JJ, Spradlin WW. Oral sodium chloride in the management of schizophrenic patients with self-induced water intoxication. J Clin Psychiatry 1985;46(1):16-19. (Pubitemid 15156259)
7. Quitkin FM, Garakani A, Kelly KE. Electrolyte-balanced sports drink for polydipsia- hyponatremia in schizophrenia. Am J Psychiatry 2003;160(2):385-386.
8. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. Am J Med 2006;119(1):71.e1-8.
9. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med 2006;119(7 Suppl 1):S79-82.
10. Gankam Kengne F, Andres C, Sattar L, Melot C, Decaux G. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 2008;101(7):583-588. (Pubitemid 351912001)
11. Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 2010;5(2):275-280.
12. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342(21):1581-1590.
13. Hawken ER, Crookall JM, Reddick D, Millson RC, Milev R, Oelva N. Mortality over a 20-year period in patients with primary polydipsia associated with schizophrenia: a retrospective study. Schizophr Res 2009;107(2-2):128-133.
14. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate and severe hyponatremia. Am J Med 2009;122(9):857-865.
15. Palm C, Pistrosch F, Herbrig K, Gross P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med 2006;119(7 Suppl 1):S87-92.
16. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al.; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355(20):2099-2112. (Pubitemid 44749318)
17. Josiassen RC, Goldman M, Jessani M, Shaughnessy RA, Albazzaz A, Lee J, et al. Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia. Biol Psychiatry 2008;64(12):1097-1100.
18. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, et al.; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21(4):705-712.
19. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry 2010;167(6):686-693.
20. Terzian C, Frye EB, Piotrowski ZH. Admission hyponatremia in the elderly: factors influencing prognosis. J Gen Intern Med 1994;9(2):89-91. (Pubitemid 24059127)
21. Goldman MB. The assessment and treatment of water imbalance in patients with psychosis. Clin Schizophr Relat Psychoses 2010;4(2):115-123